Keith Pennypacker
University of South Florida School of Medicine, USA
Title: Targeting the splenic response to brain ischemia as a treatment for stroke
Biography
Biography: Keith Pennypacker
Abstract
Many studies have recently demonstrated that the spleen plays a central role in the immune response to stroke, yet few have been successful in describing the precise splenic mechanisms leading to neurodegeneration. Our laboratory was the first to demonstrate that splenectomy decreases infarct volume. Importantly, we have spent the past decade elucidating the inflammatory signals and cell types involved. We have identified the splenic immune cells (monocytes, NK and T) that migrate to the injured hemisphere following experimental stroke. We have also shown that systemic administration of the pro-inflammatory cytokine IFNg abolished the protective effects of splenectomy, and administration of IFNg blocking antibodies reduced injury. Moreover, IFNg activates and induces expression of IP-10 in microglia. IP-10 attracts IFNg-expressing T cells to the injured hemisphere and drives a Th1 response while inhibiting the Th2 one. The spleen-derived neurodestructive signaling involves IFNg-associated activation of microglia, which leads to a feed forward signal through IP10 to attract more IFN-g. This leads to the additional expression of IP-10 in M1 microglia to further exacerbate stroke-induced neurodegeneration. This splenic response provides a therapeutic target for novels treatments to reduce stroke-induced neurodegeneration.